Business UpdateNov 6, 2026, 04:08 PM
Nkarta to Webcast Clinical Data for NKX019 in Autoimmune Diseases
AI Summary
Nkarta, Inc. announced it will host a webcast on November 9, 2026, to discuss initial clinical data from its Ntrust program evaluating NKX019 in myositis and systemic sclerosis. The data will be presented at the American College of Rheumatology (ACR) Convergence 2026. The Ntrust trials are multi-center, open-label studies assessing the safety and potential for durable remission of NKX019 in patients with autoimmune diseases.
Key Highlights
- Nkarta, Inc. will host a webcast on November 9, 2026, at 8:00 a.m. ET.
- The webcast will review initial clinical data from the Ntrust program evaluating NKX019.
- NKX019 is being evaluated in myositis and systemic sclerosis.
- The data will be presented at the American College of Rheumatology (ACR) Convergence 2026.
- The Ntrust trials (NCT06557265, NCT06733935) are evaluating NKX019 in autoimmune diseases.
- NKX019 is a CD19-targeted CAR-NK cell therapy designed to eliminate pathogenic B cells.
Price Impact
More from NKTX